3 Big Biotech Trial Results

When trial results come in for a company in the health care space, it's often do or die, make or break. In this video, Motley Fool health care analyst David Williamson takes us through three such results just in, and what's happened with shares as a result. Tranzyme (Nasdaq: TZYM  ) was today's biggest loser, with shares down a devastating 75% after results came in that its drug TZP-102 was no better than a placebo in helping gastroparesis patients. AcelRX (Nasdaq: ACRX  ) , on the other hand, was up after excellent results with its drug sufentanil nanotab pca in comparison with intravenous morphine for treating post-operative pain, and Threshold Pharmaceuticals (Nasdaq: THLD  ) experienced a jump up that has now settled back down, after some initial excitement about the results of its drug TH302 applied to maintenance therapy for soft-tissue sarcoma.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 15, 2012, at 10:49 PM, Hope4GoodFuture wrote:

    Sorry- your assessment of the TH-302 data was offensive as you clearly didn't do your homework on this one. The results reported today were incredible for sarcoma. The recently published EORTC ifosfamide plus doxirubicin trial showed overall survival of 14.3 months with extreme toxicity. The TH-302 phase II result was OS of 21.5 months. Ziopharm didn't even report OS for it's phase II trial. Ziop did say that it's phase II showed 2 year survival 40% and overall response rate of 23%. TH-302 2 year survival was 44% and ORR was 36% with significantly less toxicity. This is a huge deal in the world of sarcoma and a huge deal for a tiny $200+ million company. Any chance you could look into this further and possible retract your statement today?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2115376, ~/Articles/ArticleHandler.aspx, 12/22/2014 7:08:07 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement